Symbols / GH Stock $129.14 -0.42% Guardant Health, Inc.

Healthcare • Diagnostics & Research • United States • NMS
GH (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Diagnostics & Research
CEO Dr. Helmy Eltoukhy Ph.D.
Exch · Country NMS · United States
Market Cap 17.12B
Enterprise Value 17.73B
Income -433.19M
Sales 1.08B
FCF (ttm) -85.45M
Book/sh -1.38
Cash/sh 8.32
Employees 2,490
Insider 10d —
IPO Oct 04, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -222.53
PEG —
P/S 15.85
P/B -93.78
P/C —
EV/EBITDA -43.43
EV/Sales 16.41
Quick Ratio 4.25
Current Ratio 4.68
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -3.40
EPS next Y -0.58
EPS Growth —
Revenue Growth 48.30%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-07-29
Earnings (prior) 2026-05-07
ROA -17.15%
ROE —
ROIC —
Gross Margin 64.90%
Oper. Margin -40.23%
Profit Margin -40.10%
Shs Outstand 132.60M
Shs Float 127.81M
Insider Own 4.03%
Instit Own 105.78%
Short Float 10.17%
Short Ratio 6.57
Short Interest 12.93M
52W High 133.97
vs 52W High -3.61%
52W Low 40.35
vs 52W Low 220.05%
Beta 1.49
Impl. Vol. 0.39%
Rel Volume 0.92
Avg Volume 2.13M
Volume 1.96M
Target (mean) $131.24
Tgt Median $130.00
Tgt Low $90.00
Tgt High $190.00
# Analysts 21
Recom Strong_buy
Prev Close $129.69
Price $129.14
Change -0.42%
About

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$131.24
Mean price target
2. Current target
$129.14
Latest analyst target
3. DCF / Fair value
$-11.60
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$129.14
Low
$90.00
High
$190.00
Mean
$131.24

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-06-02 up Evercore ISI Group In-Line → Outperform $160
2026-05-27 main BTIG Buy → Buy $160
2026-05-26 main BTIG Buy → Buy $155
2026-05-08 main JP Morgan Overweight → Overweight $135
2026-05-08 main Barclays Overweight → Overweight $120
2026-05-08 main Evercore ISI Group In-Line → In-Line $95
2026-04-14 main Barclays Overweight → Overweight $115
2026-04-06 main Evercore ISI Group In-Line → In-Line $90
2026-02-24 main Piper Sandler Overweight → Overweight $130
2026-02-20 main Leerink Partners Outperform → Outperform $180
2026-02-20 main Citigroup Buy → Buy $150
2026-02-20 main Canaccord Genuity Buy → Buy $135
2026-02-20 main JP Morgan Overweight → Overweight $130
2026-02-20 main TD Cowen Buy → Buy $135
2026-02-20 main Wells Fargo Overweight → Overweight $125
2026-02-20 main Stifel Buy → Buy $130
2026-02-20 main Evercore ISI Group In-Line → In-Line $110
2026-02-20 main BTIG Buy → Buy $145
2026-02-17 init Baird — → Outperform $120
2026-01-26 main Guggenheim Buy → Buy $135
News
RSS: Latest GH news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-28 HIDALGO MEDINA MANUEL Director — 1,000 $130.06 $130,060
2026-05-27 SAIA JOHN GOMES Officer — 10,000 $125.08 $1,250,836
2026-05-22 FREEMAN CHRIS Officer — 24,406 $118.67 $2,896,360
2026-05-22 FREEMAN CHRIS Officer — 24,406 $32.86 $801,981
2026-05-20 TALASAZ AMIRALI Chief Executive Officer — 210,000 $100.95 $23,076,690
2026-05-20 HIDALGO MEDINA MANUEL Director — 1,250 $107.07 $133,864
2026-05-20 CLARK IAN THORNTON Director — 6,876 $106.90 $735,049
2026-05-20 SAIA JOHN GOMES Officer — 20,000 $105.34 $2,130,229
2026-05-20 HIDALGO MEDINA MANUEL Director — 1,000 $32.55 $32,550
2026-05-18 TARIQ MUSA Director — 116 $95.96 $11,131
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
982.02
+32.88%
739.02
+31.04%
563.95
+25.45%
449.54
Operating Revenue
982.02
+32.88%
739.02
+31.04%
563.95
+25.45%
449.54
Cost Of Revenue
349.01
+20.43%
289.80
+27.64%
227.05
+45.24%
156.32
Reconciled Cost Of Revenue
349.01
+20.43%
289.80
+27.64%
227.05
+45.24%
156.32
Gross Profit
633.01
+40.91%
449.22
+33.34%
336.90
+14.90%
293.21
Operating Expense
1,070.26
+19.88%
892.81
-0.98%
901.62
+7.64%
837.59
Research And Development
364.19
+4.73%
347.75
-5.29%
367.19
-1.77%
373.81
Selling General And Administration
706.07
+29.54%
545.06
+20.85%
451.03
-2.75%
463.78
Selling And Marketing Expense
494.66
+35.55%
364.94
+23.61%
295.23
-1.53%
299.83
General And Administrative Expense
211.41
+17.37%
180.12
+15.61%
155.80
-4.97%
163.96
Other Gand A
211.41
+17.37%
180.12
+15.61%
155.80
-4.97%
163.96
Other Operating Expenses
—
—
83.40
—
Total Expenses
1,419.27
+20.01%
1,182.61
+4.78%
1,128.67
+13.56%
993.92
Operating Income
-437.25
+1.43%
-443.59
+21.45%
-564.73
-3.74%
-544.38
Total Operating Income As Reported
-437.25
+1.43%
-443.59
+21.45%
-564.73
-3.74%
-544.38
EBITDA
-373.91
+4.16%
-390.12
+9.97%
-433.31
+29.53%
-614.91
Normalized EBITDA
-373.91
+4.16%
-390.12
+9.97%
-433.31
+29.53%
-614.91
Reconciled Depreciation
39.74
-6.25%
42.39
-1.15%
42.88
+19.24%
35.96
EBIT
-413.64
+4.36%
-432.51
+9.17%
-476.19
+26.84%
-650.87
Net Income
-416.28
+4.61%
-436.37
+8.98%
-479.45
+26.76%
-654.59
Pretax Income
-417.54
+4.03%
-435.09
+9.12%
-478.76
+26.73%
-653.45
Net Non Operating Interest Income Expense
30.20
-40.92%
51.11
+55.88%
32.79
+838.92%
3.49
Interest Expense Non Operating
3.90
+50.99%
2.58
+0.12%
2.58
+0.04%
2.58
Net Interest Income
30.20
-40.92%
51.11
+55.88%
32.79
+838.92%
3.49
Interest Expense
3.90
+50.99%
2.58
+0.12%
2.58
+0.04%
2.58
Interest Income Non Operating
34.09
-36.50%
53.69
+51.82%
35.37
+482.72%
6.07
Interest Income
34.09
-36.50%
53.69
+51.82%
35.37
+482.72%
6.07
Other Income Expense
-10.49
+75.38%
-42.60
-180.12%
53.17
+147.24%
-112.56
Other Non Operating Income Expenses
-10.49
+75.38%
-42.60
-180.12%
53.17
+147.24%
-112.56
Tax Provision
-1.26
-198.36%
1.28
+87.45%
0.69
-39.86%
1.14
Tax Rate For Calcs
0.00
-98.56%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-416.28
+4.61%
-436.37
+8.98%
-479.45
+26.76%
-654.59
Net Income From Continuing Operation Net Minority Interest
-416.28
+4.61%
-436.37
+8.98%
-479.45
+26.76%
-654.59
Net Income From Continuing And Discontinued Operation
-416.28
+4.61%
-436.37
+8.98%
-479.45
+26.76%
-654.59
Net Income Continuous Operations
-416.28
+4.61%
-436.37
+8.98%
-479.45
+26.76%
-654.59
Minority Interests
—
—
0.00
0.00
Normalized Income
-416.28
+4.61%
-436.37
+8.98%
-479.45
+26.76%
-654.59
Net Income Common Stockholders
-416.28
+4.61%
-436.37
+8.98%
-479.45
+26.76%
-654.59
Diluted EPS
-3.32
+6.74%
-3.56
+16.82%
-4.28
+33.23%
-6.41
Basic EPS
-3.32
+6.74%
-3.56
+16.82%
-4.28
+33.23%
-6.41
Basic Average Shares
125.37
+2.14%
122.75
+9.61%
111.99
+9.60%
102.18
Diluted Average Shares
125.37
+2.14%
122.75
+9.61%
111.99
+9.60%
102.18
Diluted NI Availto Com Stockholders
-416.28
+4.61%
-436.37
+8.98%
-479.45
+26.76%
-654.59
Line Item Trend 2025-12-31
Total Assets
2,013.66
Current Assets
1,466.05
Cash Cash Equivalents And Short Term Investments
1,201.60
Cash And Cash Equivalents
378.20
Other Short Term Investments
823.39
Receivables
137.85
Accounts Receivable
132.65
Other Receivables
5.20
Inventory
85.88
Prepaid Assets
—
Other Current Assets
40.72
Total Non Current Assets
547.61
Net PPE
304.76
Gross PPE
503.67
Accumulated Depreciation
-198.90
Properties
0.00
Machinery Furniture Equipment
195.87
Construction In Progress
41.25
Other Properties
158.85
Leases
107.70
Goodwill And Other Intangible Assets
103.18
Goodwill
77.26
Other Intangible Assets
25.92
Investments And Advances
—
Other Non Current Assets
139.67
Total Liabilities Net Minority Interest
2,112.97
Current Liabilities
302.73
Payables And Accrued Expenses
104.65
Payables
54.44
Accounts Payable
54.44
Other Payable
—
Current Accrued Expenses
50.21
Pensionand Other Post Retirement Benefit Plans Current
119.65
Total Tax Payable
—
Current Debt And Capital Lease Obligation
27.68
Current Capital Lease Obligation
27.68
Current Deferred Liabilities
50.75
Current Deferred Revenue
50.75
Other Current Liabilities
—
Total Non Current Liabilities Net Minority Interest
1,810.24
Long Term Debt And Capital Lease Obligation
1,682.46
Long Term Debt
1,504.00
Long Term Capital Lease Obligation
178.46
Other Non Current Liabilities
127.77
Stockholders Equity
-99.31
Common Stock Equity
-99.31
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
130.64
Ordinary Shares Number
130.64
Treasury Shares Number
0.00
Additional Paid In Capital
2,900.06
Retained Earnings
-2,994.51
Gains Losses Not Affecting Retained Earnings
-4.85
Minority Interest
—
Other Equity Adjustments
-4.85
Total Equity Gross Minority Interest
-99.31
Total Capitalization
1,404.69
Working Capital
1,163.32
Invested Capital
1,404.69
Total Debt
1,710.14
Net Debt
1,125.80
Capital Lease Obligations
206.14
Net Tangible Assets
-202.49
Tangible Book Value
-202.49
Investmentin Financial Assets
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-184.76
+22.97%
-239.86
+26.19%
-324.98
-5.01%
-309.46
Cash Flow From Continuing Operating Activities
-184.76
+22.97%
-239.86
+26.19%
-324.98
-5.01%
-309.46
Net Income From Continuing Operations
-416.28
+4.61%
-436.37
+8.98%
-479.45
+26.76%
-654.59
Depreciation Amortization Depletion
39.74
-6.25%
42.39
-1.15%
42.88
+19.24%
35.96
Depreciation And Amortization
39.74
-6.25%
42.39
-1.15%
42.88
+19.24%
35.96
Other Non Cash Items
40.96
+10.85%
36.95
+18.43%
31.20
-76.93%
135.26
Stock Based Compensation
166.22
+18.38%
140.41
+54.71%
90.76
-4.15%
94.69
Asset Impairment Charge
18.58
0.00
-100.00%
29.05
+452.25%
5.26
Deferred Tax
—
—
—
—
Deferred Income Tax
—
—
—
—
Operating Gains Losses
-13.67
—
—
—
Unrealized Gain Loss On Investment Securities
0.00
-100.00%
44.40
+155.70%
-79.71
-1122.84%
7.79
Net Foreign Currency Exchange Gain Loss
—
—
—
—
Change In Working Capital
-14.43
+76.29%
-60.86
-213.04%
53.84
-12.55%
61.56
Change In Receivables
-28.18
-31.73%
-21.39
-355.30%
8.38
+2134.13%
0.38
Changes In Account Receivables
-28.18
-31.73%
-21.39
-355.30%
8.38
+2134.13%
0.38
Change In Inventory
-14.79
-61.93%
-9.13
+11.74%
-10.35
+50.54%
-20.93
Change In Prepaid Assets
-6.35
+17.38%
-7.69
-77.54%
-4.33
-121.19%
20.44
Change In Payables And Accrued Expense
52.75
+1970.53%
-2.82
-154.32%
5.19
-91.40%
60.33
Change In Accrued Expense
—
—
—
—
Change In Payable
—
—
—
60.33
Change In Account Payable
—
—
—
60.33
Change In Other Working Capital
19.45
+4.24%
18.66
-78.08%
85.13
+762.28%
9.87
Change In Other Current Assets
0.21
+108.93%
-2.38
-282.97%
1.30
-88.90%
11.70
Change In Other Current Liabilities
-37.52
-3.90%
-36.12
-14.73%
-31.48
-55.62%
-20.23
Investing Cash Flow
-627.20
-140.02%
-261.31
-131.10%
840.25
+460.85%
149.82
Cash Flow From Continuing Investing Activities
-627.20
-140.02%
-261.31
-131.10%
840.25
+460.85%
149.82
Net PPE Purchase And Sale
-48.31
-37.68%
-35.09
-71.26%
-20.49
+73.55%
-77.46
Purchase Of PPE
-48.31
-37.68%
-35.09
-71.26%
-20.49
+73.55%
-77.46
Capital Expenditure
-48.31
-37.68%
-35.09
-71.26%
-20.49
+73.55%
-77.46
Net Investment Purchase And Sale
-519.91
-129.82%
-226.22
-126.28%
860.74
+278.72%
227.28
Purchase Of Investment
-827.23
-162.76%
-314.82
+50.46%
-635.50
-93.91%
-327.72
Sale Of Investment
307.32
+246.87%
88.60
-94.08%
1,496.23
+169.59%
555.00
Net Business Purchase And Sale
-58.99
0.00
0.00
—
Purchase Of Business
-58.99
0.00
0.00
—
Net Intangibles Purchase And Sale
—
—
—
0.00
Purchase Of Intangibles
—
—
—
0.00
Net Other Investing Changes
—
—
1.53
—
Financing Cash Flow
671.13
+67482.83%
-1.00
-100.21%
477.38
+352.46%
-189.09
Cash Flow From Continuing Financing Activities
671.13
+67482.83%
-1.00
-100.21%
477.38
+352.46%
-189.09
Net Issuance Payments Of Debt
402.50
0.00
0.00
+100.00%
-0.07
Issuance Of Debt
402.50
0.00
0.00
0.00
Repayment Of Debt
—
—
—
-0.07
Long Term Debt Issuance
402.50
0.00
0.00
0.00
Long Term Debt Payments
—
—
—
-0.07
Net Long Term Debt Issuance
402.50
0.00
0.00
+100.00%
-0.07
Net Common Stock Issuance
299.99
0.00
-100.00%
493.12
0.00
Common Stock Payments
-45.01
0.00
0.00
—
Repurchase Of Capital Stock
-45.01
0.00
0.00
—
Proceeds From Stock Option Exercised
32.81
+121.11%
14.84
+40.52%
10.56
-11.57%
11.94
Net Other Financing Charges
-64.17
-305.24%
-15.83
+39.79%
-26.30
+86.92%
-201.03
Changes In Cash
-140.83
+71.96%
-502.16
-150.59%
992.65
+384.64%
-348.74
Effect Of Exchange Rate Changes
0.49
+127.74%
-1.77
-94.29%
-0.91
+43.06%
-1.60
Beginning Cash Position
629.75
-44.45%
1,133.69
+698.66%
141.95
-71.17%
492.29
End Cash Position
489.42
-22.28%
629.75
-44.45%
1,133.69
+698.66%
141.95
Free Cash Flow
-233.07
+15.23%
-274.94
+20.41%
-345.46
+10.72%
-386.92
Interest Paid Supplemental Data
3.77
0.00
0.00
—
Income Tax Paid Supplemental Data
0.87
-13.70%
1.01
-48.86%
1.97
+47.93%
1.33
Amortization Of Securities
-5.88
+13.24%
-6.77
+50.01%
-13.55
-394.93%
4.59
Common Stock Issuance
345.00
0.00
-100.00%
493.12
0.00
Issuance Of Capital Stock
345.00
0.00
-100.00%
493.12
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category